Introduction
============

Chronic hepatitis C is due to a chronic infection by the hepatitis C virus (HCV). It develops in 75--85% of acute infections \[[@b1]\]. The prevalence of chronic hepatitis C was estimated in 2004 to 232 196 patients \[[@b2],[@b3]\] and in 2012 to between 150 000 and 190 306 patients \[[@b4],[@b5]\]. In the absence of an effective treatment, about 30% of infected patients develop cirrhosis and hepatocellular carcinoma after 20 years \[[@b6]--[@b8]\]. In contrast, patients with a sustained viral response (SVR) have a life expectancy similar to the general population \[[@b8]\].

Available treatments include pegylated interferon (PEGINF), ribavirin (RBV) and protease inhibitors (PIs). Recommended treatment regimens differ depending on the genotype of the virus, the level of liver fibrosis, HIV coinfection and the existence of prior treatments \[[@b9]--[@b11]\]. These treatments, although fairly effective, have some limitations. First, their associated SVR rates do not exceed 75% for genotype 1 infections in noncirrhotic naive patients \[[@b12]\], and for cirrhotic patients SVR drops to 62% at best. In addition, treatment durations are long, between 24 and 48 weeks. Third, they have tolerance issues with up to 26% premature discontinuation \[[@b13],[@b14]\], that could result in reduced effectiveness in real life. Finally, all treatment regimens require the addition of pegylated interferon, which cannot be used in 15--45% of patients, because of tolerance issues and contraindications \[[@b15],[@b16]\].

In this context, the arrival of a new therapeutic class, sofosbuvir (SOF), represents a new hope for many patients. Indeed, SOF-based treatments have shown SVR rates over 90% across genotypes, higher than the current treatments with tolerance profiles similar to placebo \[[@b17]--[@b21]\]. SOF treatments are also shorter than their counterpart. Given current healthcare budget constraints, we decided to assess the cost-effectiveness of SOF against current treatment options in the French context.

Method
======

Given the slow evolution of chronic HCV infections, and because treatments benefits are expected in the long term, a life-time horizon model was used. SOF treatments were compared with the recommended therapeutic strategies \[[@b9]--[@b11]\] for all chronically infected patients, regardless of their fibrosis stage, treatment history or HIV confection. G1/4 experienced patients and G4 coinfected patients were excluded because no clinical data were available for SOF. In addition, G3 naive coinfected patient was excluded because available clinical data (SOF + RBV treatment for 24 weeks) did not match the recommended SOF regimen (SOF + PEGINF + RBV for 12 weeks). Excluded patients accounted for approximately one quarter of chronic infection prevalence in France \[[@b1],[@b15],[@b16],[@b22],[@b23]\]. The population characteristics were based on French epidemiology \[[@b1],[@b22],[@b23]\] (Table [1](#tbl1){ref-type="table"}).

###### 

Distributions of subgroups, comparators and treatment efficacy

  Subgroup                    Proportion (%)   Cirrhotic (%)   Currently recommended treatment   SVR (cirrhotic/noncirrhotic)   Source                              Sofosbuvir                 SVR (cirrhotic/non cirrhotic)   Source
  --------------------------- ---------------- --------------- --------------------------------- ------------------------------ ----------------------------------- -------------------------- ------------------------------- ------------------------------------
  G1 naive                    56.8             40.0            Télaprévir + PEGINF + RBV (48W)   75.4/61.0                      Jacobson *et al*. 2011 \[[@b12]\]   SOF + PEGINF + RBV (12W)   91.3/80.8                       Lalezary *et al*. 2013 \[[@b33]\]
  G1 naive coinfected         4.3              40.0            Télaprévir + PEGINF + RBV (48W)   72.1/61.0                      Sulkowski *et al*. AASLD 2012       SOF + PEGINF + RBV (12W)   77.1/60.0                       Sulkowski *et al*. 2013 \[[@b36]\]
  G2 naive                    3.1              40.0            PEGINF+RBV (24W)                  81.5/61.5                      Lawitz *et al*. 2013 \[[@b21]\]     SOF+RBV (12W)              98.3/90.9                       Lawitz *et al*. 2013 \[[@b21]\]
  G2 experience               2.0              50.0            PEGINF+RBV (48W)                  35.0/35.0                      Lagging *et al*. 2013 \[[@b37]\]    SOF+RBV (12W)              91.0/87.5                       Zeuzem *et al*. 2013 \[[@b38]\]
  G2 PEGINF ineligible        2.9              40.0            None                              0/0                            --                                  SOF+RBV (12W)              91.8/93.3                       Jacobson *et al*. 2013 \[[@b17]\]
  G2 naive coinfected         0.4              40.0            PEGINF+RBV (48W)                  86.0/61.1                      Labarga *et al*. 2012 \[[@b39]\]    SOF+RBV (12W)              88.0/100.0                      Lalezary *et al*. 2013 \[[@b33]\]
  G2 experienced coinfected   0.4              50.0            PEGINF+RBV (48W)                  86.0/61.1                      Labarga *et al*. 2012 \[[@b39]\]    SOF+RBV (12W)              92.3/100.0                      Lalezary *et al*. 2013 \[[@b33]\]
  G3 naive                    7.2              40.0            PEGINF+RBV (24W)                  71.2/29.7                      Lawitz *et al*. 2013 \[[@b21]\]     SOF+ PEGINF + RBV (12W)    100.0/83.3                      Lawitz *et al*. 2013 \[[@b40]\]
  G3 experienced              4.7              50.0            PEGINF+RBV (48W)                  35.0/35.0                      Lagging *et al*. 2013 \[[@b37]\]    SOF+ PEGINF + RBV (12W)    83.8/83.3                       Lawitz *et al*. 2013 \[[@b40]\]
  G3 ineligible PEGINF        6.2              40.0            None                              0/0                            --                                  SOF+RBV (24W)              85.0/60.0                       Zeuzem *et al*. 2013 \[[@b38]\]
  G3 experienced coinfected   0.5              50.0            PEGINF+RBV (48W)                  86.0/61.1                      Labarga *et al*. 2012 \[[@b39]\]    SOF+RBV (24W)              100.0/80.0                      Sulkowski *et al*. 2013 \[[@b36]\]
  G4/5/6 naive                11.6             40.0            PEGINF+RBV (48W)                  50.0/38.6                      Manns *et al*. 2001                 SOF + PEGINF+ RBV (12W)    100.0/50.0                      Lawitz *et al*. 2013 \[[@b20]\]

W: Weeks, G: Genotype, PEGINF: pegylated interferons, RBV: ribavirine, SOF: sofosbuvir.

Model structure
---------------

A Markov model was used (Fig. [1](#fig01){ref-type="fig"}). It is based on a previously published model that is described elsewhere \[[@b24]\]. Briefly, the model includes eleven states with two states for SVR patients, two absorbing states and one treatment state.

![Markov tree.](jvh0022-0376-f1){#fig01}

Patients entered the model at treatment and were divided according to fibrosis stage, HCV genotype, prior treatment and coinfection distribution in the French population (Table [1](#tbl1){ref-type="table"}). Patient could be treated by either currently recommended treatment \[[@b9]--[@b11]\] or by SOF. At the end of treatment, patients were moved either to an SVR state (SVR noncirrhotic, SVR cirrhotic) or a non-SVR state (noncirrhotic, cirrhotic) (Table [1](#tbl1){ref-type="table"}). Retreatments, relapses and recurrences were not considered in the model. The impact of relapses and recurrences was tested in the sensitivity analysis (dotted arrow in Fig. [1](#fig01){ref-type="fig"}). Fibrosis in SVR patients remained stable during lifetime and SVR patients had a mortality rate identical to that of the general population \[[@b8]\]. Fibrosis stage progressed in non-SVR patients and they could develop complications. At every stage, non-SVR patients had a background mortality rate based on the general population. In addition, patients with complications had a HCV-specific mortality rate.

The duration of the first eight cycles was three monthly to match treatment durations; subsequent treatment, cycles were yearly.

Clinical data
-------------

The proportions of patients in each subgroup, treatments, effectiveness and the duration are shown in Table [1](#tbl1){ref-type="table"}. Serious adverse event rates (grade 3/4 WHO classification) of comparators and sofosbuvir were taken into account, and their frequencies were derived from clinical trial data (data not shown). Premature discontinuations due to adverse events were considered in the calculation of the effective treatment durations.

The transition probabilities of noncirrhotic to cirrhotic were calculated from the values used in a recent publication for the French population \[[@b25]\]. The transition probability from noncirrhotic to cirrhotic was extrapolated from this data using the stages distribution observed in the SOF clinical trials (77% of F0-F1-F2 patients and 23% of F3 patients). Other transition probabilities were based on the literature \[[@b26],[@b27]\] (Fig. [1](#fig01){ref-type="fig"}).

Utility data
------------

In the absence of French utility data, utilities were derived from Hsu *et al*. 2012. The model also took into account the disutility related to treatment. These were determined from clinical trials sofosbuvir \[[@b20]\], telaprevir NICE notice \[[@b28]\] and the literature \[[@b29]\]. Data are presented in Table [2](#tbl2){ref-type="table"}.

###### 

Parameters used in the model

  Parameter                    Baseline value   Standard deviation   Distribution   Source
  ---------------------------- ---------------- -------------------- -------------- ------------------------------
  Utility (annual)                                                                  
   Sofosbuvir                  −0.08            0.054                Uniform        Lawitz, 2013 \[[@b20]\]
   PEGINF + RBV                −0.15            0.05                 Gamma          Wright 2006 \[[@b29]\]
   Telaprevir                  −0.14            0.01                 Gamma          NICE TA252 \[[@b28]\]
   Noncirrhotic                0.57             0.01                 Beta           PC Hsu, 2012 \[[@b41]\]
   Cirrhotic                   0.51             0.01                 Beta           PC Hsu, 2012 \[[@b41]\]
   SVR                         +0.13            0.04                 Gamma          PC Hsu, 2012 \[[@b41]\]
   Decompensated cirrhosis     0.56             0.03                 Beta           PC Hsu, 2012 \[[@b41]\]
   Hepatocarcinoma             0.56             0.03                 Beta           PC Hsu, 2012 \[[@b41]\]
   Liver transplantation       0.56             0.03                 Beta           PC Hsu, 2012 \[[@b41]\]
   Postliver transplantation   0.64             0.03                 Beta           PC Hsu, 2012 \[[@b41]\]
  Cost (annual)                                                                     
   Noncirrhotic                240 €            397 €                Gamma          Schwarzinger 2013 \[[@b31]\]
   Cirrhotic                   1081 €           2642 €               Gamma          Schwarzinger 2013 \[[@b31]\]
   Noncirrhotic SVR            -- €             -- €                 Gamma          Assumption
   Cirrhotic SVR               178 €            178 €                Gamma          Assumption
   Decompensated cirrhosis     11 719 €         16 895 €             Gamma          Schwarzinger 2013 \[[@b31]\]
   Hepatocarcinoma             14 550 €         19 770 €             Gamma          Schwarzinger 2013 \[[@b31]\]
   Liver transplantation       75 494 €         89 294 €             Gamma          Schwarzinger 2013 \[[@b31]\]
   Postliver transplantation   3234 €           7176 €               Gamma          Schwarzinger 2013 \[[@b31]\]
   Sofosbuvir                  723 €            46 €                 Uniform        Assumption: 10% variation
   Ribavirine                  223 €            11 €                 Uniform        Assumption: 10% variation
   PEGINF 2a                   157 €            8 €                  Uniform        Assumption: 10% variation
   Telaprevir                  2296 €           115 €                Uniform        Assumption: 10% variation

SVR: Sustained viral response, PEGINF: pegylated interferons, RBV: ribavirine.

Cost data
---------

All costs were expressed in Euro 2013. Only direct medical costs were taken into account. Costs were estimated from a society point of view.

The price used for Sofosbuvir was the price in effect during the early access program for patients with severe fibrosis. The price of other treatments was based on the tax-inclusive retail price. The total cost of treatment took into account the average treatment duration.

The costs of serious adverse events were calculated based on their associated treatments strategies. Treatments strategies were based on telaprevir treatment guidelines, data from the literature \[[@b30]\] and expert opinions.

Monitoring costs were determined based on the recommended follow-up of chronically infected patients distinguishing cirrhotic patients from noncirrhotic \[[@b9]--[@b11]\]. The costs of laboratory tests, radiological examination and consultations were based on the prices fixed by the French national health insurance.

Management costs were based on a French cost study \[[@b31]\]. No cost was associated with SVR noncirrhotic patients as they were considered cured. Costs associated with the management of SVR cirrhotic patients were estimated based on follow-up recommendations from the French National Authority of Health (HAS) \[[@b32]\]. The cost data are presented in Table [2](#tbl2){ref-type="table"}.

Analysis
--------

The incremental cost--effectiveness ratio (ICER) was calculated for the life expectancy adjusted for quality of life (QALY). Costs and QALY were discounted at 2.5% per annum.

The robustness of the model was tested using probabilistic and deterministic sensitivity analysis. In the deterministic analysis, all the parameters were tested at −25% and +25% of baseline value. Only the ten parameters with the greatest influence on the results are presented. The results are presented with a Tornado graph (Fig. [2](#fig02){ref-type="fig"}).

![Deterministic sensitivity analysis TP: transition probabilities, SVR: sustained viral response, HCC: Hepatocarcinoma, ICER: Incremental Cost--Effectiveness Ratio.](jvh0022-0376-f2){#fig02}

The probabilistic sensitivity analysis was conducted for utilities, costs, transition probabilities and treatment efficacy. It was based on a Monte-Carlo process with 1000 simulations. Parameters were varied randomly according to their associated distributions. The distributions used for the costs and utilities are shown in Table [2](#tbl2){ref-type="table"}. For transition probabilities and efficacies a beta distribution was used, with a mean equal to the parameter baseline value and a standard deviation equal to 10% of the baseline value. The result is presented with an acceptability curve (Fig. [3](#fig03){ref-type="fig"}).

![Acceptability curve.](jvh0022-0376-f3){#fig03}

Analysis was also performed for each fibrosis stage (F0 to F4), considering that all patient entered the model at the same stage. All parameters were unchanged, except for the proportion of cirrhotic patients and the noncirrhotic to cirrhotic transition probabilities. Transition probabilities were recalculated to match the fact that all patients entered the model at the same stage for F0 to F3. The analyses were performed using Excel version 2013 (Microsoft Corporation, Redmond, WA, USA).

Results
=======

Main analysis
-------------

The nonactualized and actualized results are shown in Table [3](#tbl3){ref-type="table"}. ICER of sofosbuvir compared to currently recommended treatments was estimated at € 16 278 €/QALY. Results for each fibrosis stage are shown in Table [4](#tbl4){ref-type="table"}.

###### 

Results of the cost-effectiveness analysis

                                             Sofosbuvir   Comparators
  ------------------------------------------ ------------ ---------------
  Nonactualized                                           
   Cost of treatment                         67 291 €     24 186 €
   Cost of care                              7239 €       23 772 €
   Total cost                                74 531 €     47 958 €
   Life expectancy (years)                   33.8         30.2
   Quality adjusted life expectancy (QALY)   22.9         19.4
  Actualized                                              
   Total cost                                72 213 €     39 789 €
   Life expectancy (years)                   22.3         20.4
   QALY                                      15.0         13.0
  Sofosbuvir versus Comparators                           
   Incremental cost                                       32 423 €
   Incremental life expectancy                            1.8
   Incremental QALY                                       2.0
   ICER (life expectancy)                                 17 817 €/LY
   ICER (QALY)                                            16 278 €/QALY

ICER: Incremental Cost--Effectiveness Ratio, LY: Life Year.

###### 

ICER by Stage

  ICER by stage   
  --------------- ---------------
  F0              40 653 €/QALY
  F1              31 348 €/QALY
  F2              17 651 €/QALY
  F3              11 359 €/QALY
  F4              12 080 €/QALY

Sensitivity analyses
--------------------

Figure [2](#fig02){ref-type="fig"} shows the deterministic sensitivity analyses for the ten parameters that have the greatest impact on the incremental cost--effectiveness ratio. Overall, ICER varied at most between 5000 €/QALY and 24 000 €/QALY for a 25% variation of baseline parameters.

Figure [3](#fig03){ref-type="fig"} shows the probability that the ICER is below a given threshold. The probability that the ICER of treatment sofosbuvir is \<€ 40 000/QALY was 99.5%.

Discussion
==========

This study showed that sofosbuvir, at the early access program price, is a cost-effective strategy in chronic HCV infection treatments at a commonly accepted threshold of € 40 000/QALY.

Sensitivity analyses confirmed the robustness of these results. Probabilistic analyses showed that close to a 100% of simulations were below 40 000 € per QALY. In our model, using sofosbuvir lead to a lower overall cost of the disease as more patients were cured leading to fewer patients developing expensive-to-treat advance liver conditions. This reduction in overall disease cost is the main factor explaining the observed small ICER.

The model was based on the most robust data available in the literature. However, the lack of available data for some parameters led us to make several assumptions. Firstly, the model does not discern F0 to F3 stage. Indeed, the efficacy of sofosbuvir in clinical trials of over 90% SVR was available only for the group of noncirrhotic patients without differentiating stage of fibrosis. We hypothesized that treatment efficacy was similar between F0, F1, F2 and F3 due to the high cure rates. Moreover, transition probabilities took into account the distribution of fibrosis stage observed in sofosbuvir clinical trials in order to be as close as possible to the clinical trial data, and thus have a higher confidence in the efficacy rates that were used. Furthermore, by stage analysis shows that ICERs are lower in higher stages. Considering that higher stages have a higher probability of reaching F4, this is coherent with the determinist analysis that showed that higher transition rates are associated with lower ICER. Secondly, in the absence of a comparator arm in the G1 naive sofosbuvir clinical trial, the effectiveness of telaprevir was based on clinical trial data available from the literature. This was deemed conservative as the population of SOF trial contained more difficult to treat patients with advanced disease, high BMI, low platelets and black ethnic status than the pivotal trial evaluating telaprevir \[[@b12],[@b33]\]. Thirdly, the baseline model did not take into account the risk of reinfection and recurrence. However, this hypothesis was tested in the deterministic analysis and was not found to have an important impact on the ICER. Finally, genotype 3 naive coinfected patients were excluded from the analysis because available data for these patients does not match recommended regimen in sofosbuvir authorization. However, the overall impact on the ICER of including this population would have been negligible in view of the very limited size of that specific population.

Thus, these analyses showed that the use of sofosbuvir in the French context to treat chronically HCV infected patient is more effective and efficient than other available options defined by PIs and PEGINF. The relatively low ICER resulted from the higher SVR achieved and the subsequent reduction in the cost of the disease. This can be seen in the 12% gain in life expectancy in the sofosbuvir arm in the model. Those results are based on clinical trial data, which usually show better efficacy and safety. Indeed, recent results for protease inhibitors have shown that real life treatment completion was much lower than in clinical trials \[[@b34]\]. Similar results have also been observed for INFPEG/RBV treatments \[[@b35]\]. However, we expect that sofosbuvir, because of shorter treatment duration, better safety profile, inclusion of difficult to treat patient populations within the trials, PEGINF-free regimen and all oral treatments will result in a similar efficacy in real life. Furthermore, these results are probably conservative because no account was taken of comorbidities and extra hepatic manifestations associated with HCV such as diabetes, high blood pressure, kidney failure that would also be reduced with a more effective treatment. Thus, we expect even lower ICER in real life.

In conclusion, these analyses suggest that sofosbuvir is a cost-effective option for treating chronic hepatitis C regardless of fibrosis stage in French patients. Given these results, its use should be recommended in every eligible patients awaiting treatment.
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